Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3SBioSTU:83B +1.04%89 ROC (Joel Greenblatt) % is 314.96% as of Dec. 2025, which is 572% above its 10-year median of 46.89. GuruFocus rates STU:83B with a GF Score™ of 89/100 and a GF Value™ of €1.45 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 1,323 Biotechnology companies, 3SBio ranks better than 96.15% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. 3SBio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 314.96%.
The historical rank and industry rank for 3SBio's ROC (Joel Greenblatt) % or its related term are showing as below:
STU:83B'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 30.87 Med: 46.89 Max: 179.47
Current: 179.47
During the past 12 years, 3SBio's highest ROC (Joel Greenblatt) % was 179.47%. The lowest was 30.87%. And the median was 46.89%.
STU:83B's ROC (Joel Greenblatt) % is ranked better than 96.15% of 1323
companies
in the Biotechnology industry
Industry Median: -297.52
vs STU:83B: 179.47
3SBio's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 29.50% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
The historical data trend for 3SBio's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:83B vs VRTX, REGN, ALNY: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, 3SBio's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3SBio ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3SBio's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where 3SBio's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 314.96% mean?
3SBio (STU:83B) has a ROC (Joel Greenblatt) % of 314.96% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on 3SBio and its competitors. This is 572% above median its historical median of 46.89. Over the past decade, 3SBio's ROC (Joel Greenblatt) % has ranged from 30.87 to 179.47. According to the industry distribution chart, 3SBio ranks #51 out of 1323 companies in the Biotechnology industry, placing it in the top 3.9%.
Is 3SBio's ROC (Joel Greenblatt) % too high?
3SBio's current ROC (Joel Greenblatt) % of 314.96% is 572% above median its 10-year median of 46.89. Over the past 10 years, this metric has ranged from a low of 30.87 to a high of 179.47. Based on the distribution chart, 3SBio ranks #51 out of 1323 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, 3SBio has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 3SBio's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 3SBio ranks #51 out of 1323 companies for ROC (Joel Greenblatt) %. This places 3SBio in the top 4% of its industry — outperforming the majority of peers. Historically, 3SBio's own ROC (Joel Greenblatt) % has ranged from 30.87 to 179.47 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on 3SBio and its competitors. 3SBio's current ROC (Joel Greenblatt) % is 314.96%, which is 572% above median its own 10-year median of 46.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3SBio stock overvalued right now?
Based on GuruFocus' analysis, 3SBio (STU:83B) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.45, compared to a current price of €1.88 — trading 29.7% above its estimated fair value. The current ROC (Joel Greenblatt) % is 314.96%, which is 572% above median its 10-year median of 46.89. 3SBio's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For 3SBio (STU:83B), the current ROC (Joel Greenblatt) % is 314.96% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3SBio (STU:83B) Overvalued in 2026?
Based on GuruFocus' analysis, 3SBio stock appears to be overvalued.
The current stock price of €1.88 is trading 29.7% above its estimated GF Value™ of €1.45.
GuruFocus considers 3SBio to be Modestly Overvalued.
Key valuation signals for STU:83B:
ROC (Joel Greenblatt) %: 314.96% (572% above median its 10-year median of 46.89)
GF Value™: €1.45 vs. price of €1.88 (29.7% above fair value)
No single metric tells the full story. See the STU:83B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3SBio Inc is an investment holding company. It is a primary biotechnology company. The company is principally engaged in the development, production, marketing and sale of biopharmaceutical products in the People's Republic of China. The group has only one operating segment. It has presence in Chinese mainland, USA, Other countries/regions. The majority of revenue comes from USA. The core commercialized products of the group include several bio-pharmaceutical drugs, namely, TPIAO, recombinant human erythropoietin (rhEPO) products EPIAO and SEPO, Yisaipu and Cipterbin, and a small molecule drug, Mandi series of minoxidil drugs.
89GF Score
Get the complete analysis for STU:83B
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:83B has been successfully added to your 
